Omeprazole Liconsa

Omeprazole, the active ingredient in Omeprazole Liconsa, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal disorders such as gastro‑esophageal reflux disease and peptic ulcer disease.

GNH USA supplies Omeprazole Liconsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance across EU‑origin products. The company provides full documentation and supports import procedures for global partners.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions.

- Gastroesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by reducing gastric acidity. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by suppressing acid. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Omeprazole may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit. - Flatulence: increased intestinal gas. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Low magnesium levels: can cause muscle weakness, tremors, or cardiac arrhythmia. - Vitamin B12 deficiency: may develop with long‑term use, leading to anemia. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare skin blistering disorders. - Liver enzyme elevation: signs of hepatic injury detectable in blood tests.

When prescribing Omeprazole, clinicians should consider several safety precautions to minimize risks. - Assess renal function: adjust use in patients with severe renal impairment. - Review concomitant medications: monitor for reduced efficacy of drugs such as clopidogrel. - Use the lowest effective dose: limit duration to the shortest period necessary. - Discontinue on hypersensitivity: stop immediately if allergic reactions occur. - Evaluate pregnancy and lactation status: prescribe only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activation leading to decreased efficacy. - Atazanavir: decreased absorption and therapeutic effect. - High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR and bleeding risk. - Digoxin: may raise serum concentrations. - Diazepam: enhanced sedation from higher plasma levels.